| Literature DB >> 36042860 |
Tigist Kebede Mulugeta1,2, Dejene Hailu Kassa2.
Abstract
Background: In low-income nations such as Ethiopia, noncommunicable diseases (NCDs) are becoming more common. The Ethiopian Ministry of Health has prioritized NCD prevention, early diagnosis, and management. However, research on the readiness of public health facilities to address NCDs, particularly hypertension and type II diabetes mellitus, is limited.Entities:
Keywords: Readiness
Year: 2022 PMID: 36042860 PMCID: PMC9420406 DOI: 10.7717/peerj.13797
Source DB: PubMed Journal: PeerJ ISSN: 2167-8359 Impact factor: 3.061
Figure 1Sample facilities recruited for SARA.
Domains and indicators used for assessing the readiness of primary health care units to manage diabetes and hypertension.
| Domain | Indicator | Data collection and description |
|---|---|---|
| Basic amenities | Sanitation facilities | Observed availability of functioning |
| Communication equipment’s | Sanitation facilities | |
| Consultation room | Communication equipment’s | |
| Water source, power source, emergency transportation and computer with internet | Consultation room | |
| Staff training and guidelines | Guidelines for the diagnosis and management of DM and HPN | Observed availability of National Standard Treatment hard copy of Guidelines for DM and HPN. |
| Staff trained in the diagnosis and management of DM and HPN | Observed availability of at least one trained staff providing | |
| DM, HPN services who had completed refresher courses for the diagnosis and management of DM, HPN. | ||
| Basic diagnostic equipment | DM: weight scale, height scale and measuring tape and glucometer. | Observed availability of functioning weight scale, height scale and glucometer with test strips and urine dipstick protein and ketone |
| HPN: stethoscope and blood pressure (BP) apparatus | Observed availability of functioning digital or manual | |
| BP apparatus in the facility | ||
| Basic medicines | DM: metformin, glibenclamide and insulin injection. | Observed availability of a first-line regimen that had not expired; metformin (for obese patients), glibenclamide (for non-obese patients) and insulin injection for DM |
| HPN: thiazide diuretics, ACE inhibitors, beta | Observed availability of at least one type of thiazide diuretics as a first-line regimen for hypertension atleast one type of (ACE inhibitor+beta blocker furosemide). |
Study facilities and their location.
| Facility type | Rural facilities | Urban facilities | Total | |||
|---|---|---|---|---|---|---|
| n | % | n | % | n | % | |
| Health centers | 46 | 56 | 17 | 23 | 63 | 76.8 |
| Primary hospital | 5 | 6 | 8 | 9.7 | 13 | 16 |
| General hospital | 2 | 2.4 | 1 | 1.2 | 3 | 2.4 |
| NGO clinics | 3 | 3.6 | 0 | 0 | 3 | 3.6 |
| Total | 56 | 68.3 | 26 | 31.7 | 82 | 100 |
Figure 2The availability of basic amenities in the sampled health facilities.
Figure 3The availability of guidelines and trained staff for DM and HPN management.
Figure 4Availability of basic screening equipment for DM.
Figure 5The availability of basic diagnostic materials for DM management.
Figure 6(A) The availability of basic medicines for the management of HPN and (B) the availability of basic medicines for the management of DM.
Association of facility type, facility location and the availability of guidelines and trained staff for the management of HPN and DM.
| Variables | Categories | HPN management and treatment | DM management and treatment | ||||
|---|---|---|---|---|---|---|---|
| Ready | Not ready | Ready | Not ready | ||||
| Facility type | Health center | 1,152 | 52 | 0.001 | 12 | 51 | 0.001 |
| Primary Hospital | 76 | 6 | 7 | 6 | |||
| General Hospital | 3 | 0 | 3 | 0 | |||
| Others | 2 | 1 | 2 | 1 | |||
| Total | 23 | 59 | 24 | 58 | |||
| Facilities location | Rural | 47 | 9 | 0.001 | 48 | 8 | 0.00 |
| Urban | 12 | 14 | 10 | 16 | |||
| Total | 59 | 23 | 58 | 24 | |||
| Availability of guideline for NCD | Yes | 1 | 14 | 0.000 | 3 | 12 | 0.00 |
| No | 58 | 9 | 55 | 12 | |||
| Total | 59 | 23 | 15 | 67 | |||
| Staff trained for NCD | Yes | 21 | 22 | 0.000 | 3 | 18 | 0.00 |
| No | 38 | 1 | 55 | 6 | |||
| Total | 59 | 23 | 21 | 61 | |||
Notes:
P value ≤ 0.05.
P value ≤ 0.01.
Availability of diagnostic equipment for HPN and DM management.
| Diagnostic equipment’s for HPN management and treatment | ||||
|---|---|---|---|---|
| Equipment | Category | HPN management and treatment | ||
| Ready | Not ready | |||
| Stethoscope | Yes | 23 | 57 | 1.000 |
| No | 0 | 2 | ||
| Total | 23 | 59 | ||
| Blood pressure apparatus | Yes | 23 | 58 | 1.000 |
| No | 0 | 1 | ||
| Total | 23 | 59 | ||
| Diagnostic equipment’s for DM management and treatment | ||||
| Measuring tape | Yes | 17 | 7 | |
| No | 7 | 51 | 0.000 | |
| Total | 24 | 58 | ||
| Adult weight scale | Yes | 24 | 55 | 0.348 |
| No | 0 | 3 | ||
| Total | 24 | 58 | ||
| Stadio-metere | Yes | 24 | 45 | 0.008 |
| No | 0 | 13 | ||
| Total | 24 | 58 | ||
| Blood glucose test | Yes | 23 | 18 | |
| No | 1 | 40 | 0.000 | |
| Total | 24 | 58 | ||
| Urine dipstick-protein and ketone | Yes | 23 | 20 | |
| No | 138 | 38 | 0.000 | |
| Total | 24 | 24 | ||
Notes:
P value ≤ 0.05.
P value ≤ 0.01.
The bivariate analysis of basic medicines for the management of HPN with readiness of the PHCU.
| Variables | Categories | HPN management and treatment | ||
|---|---|---|---|---|
| Ready | Not ready | |||
| At least one type of ACE inhibitor | Yes | 17 | 13 | 0.013 |
| No | 6 | 46 | ||
| Total | 23 | 59 | ||
| At least one type of thiazide diuretic | Yes | 22 | 13 | 0.000 |
| No | 1 | 146 | ||
| Total | 23 | 59 | ||
| At least one type of Beta blocker | Yes | 12 | 3 | 0.000 |
| No | 11 | 56 | ||
| Total | 23 | 59 | ||
| At least one type of calcium channel blockers ( | Yes | 22 | 12 | 0.000 |
| No | 1 | 48 | ||
| Total | 1 | 59 | ||
Notes:
P value ≤ 0.05.
P value ≤ 0.01.
The bivariate analysis of basic medicines for the management of DM with readiness of the PHCU.
| Variables | DM management and treatment | ||
|---|---|---|---|
| Ready | Not ready | ||
| Metformin cap/tab | 23 | 7 | 0.000 |
| 1 | 51 | ||
| 24 | 58 | ||
| Glibenclamide cap/tab | 23 | 6 | 0.000 |
| 1 | 49 | ||
| 24 | 58 | ||
| Insulin regular injectable | 20 | 5 | 0.000 |
| 4 | 3 | ||
| 24 | 58 | ||
| Glucose 50% injectable | 24 | 25 | 0.000 |
| 0 | 33 | ||
| 24 | 58 | ||
| Gliclazide tablet or Glipizide tablet | 2 | 1 | 0.0204 |
| 22 | 57 | ||
| 24 | 24 | ||
Factors associated with the readiness of the facilities to provide HPN management at the PHCU adjusted for confounding variables.
| Variables | COR [95% CI] | AOR [95% CI] |
|---|---|---|
| Facility type | ||
| Health centre | 1.0 | 1.0 |
| Primary Hospital | 5.5 [1.5–19.6] | 3.6 [0.9–14.9] |
| General Hospital | 7,636,790,166 | - |
| Others | 9.5 [0.8–0.113] | 22.2 [1.7–297.9] |
| Location of the Facilities | ||
| Rural | 1.0 | 1.0 |
| Urban | 6.0 [2.1–17.4] | 8.2 [2.4–28.5] |
| Guideline for CVD | ||
| Not available | 1.0 | 1.0 |
| Available | 0.011 [0.001–0.095] | 0.005 [0.000–0.091] |
| Staff trained for HPN management | ||
| Not trained | 1.0 | 1.0 |
| Trained | 0.025 [0.003–0.20] | 0.066 [0.008–0.564] |
| Stethoscope | ||
| Available | 1.0 | 1.0 |
| Not available | 0.000 | - |
| BP apparatus | ||
| Available | 1.0 | 1.0 |
| Not available | 0.000 | - |
| Groups of medicine | ||
| ACE inhibitor | 1.0 | 1.0 |
| Thiazide groups | 0.242 [0.083–0.703] | 0.095 [0.016–0.570] |
| Beta blockers | 0.013 [0.002–0.105] | 0.012 [0.001–0.135] |
| Calcium channel blocker | 0.049 [0.012–0.203] | 0.011 [0.001–0.149] |
Notes:
P value ≤ 0.05.
P value ≤ 0.01.
Factors associated with the readiness of the facilities to provide DM management at the PHCU adjusted for confounding variables.
| Variables | COR [95% CI] | AOR [95% CI] |
|---|---|---|
| Facility type | ||
| Health centre | 1.0 | 1.0 |
| Primary Hospital | 4.958 [1.4–17.5] | 2.2 [0.5–9.5] |
| General Hospital | – | – |
| Others | 8.5 [0.7–101.6] | 11.9 [0.8–0.186.0] |
| Facilities location | ||
| Rural | 1.0 | 1.0 |
| Urban | 9.6 [3.2–28.5] | 11.1 [3.13–39.36] |
| Guideline for NCD | ||
| Not available | 1.0 | 1.0 |
| Available | 0.055 [0.013–0.22] | 0.31 [0.004–0.231] |
| Staff trained for DM management | ||
| Trained | 1.0 | 1.0 |
| Not trained | 0.18 [0.004–0.08] | 0.055 [0.009–0.336] |
| Adult weight scale | ||
| Not available | 1 | 1 |
| Available | 0.000 | - |
| Measuring tape (ref.) | ||
| Not available | 1.0 | 1.0 |
| Available | 0.057 [0.017–0.18] | 0.055 [0.009–0.336] |
| Stadio-meter | ||
| Available | 1 | 1 |
| Not available | - | - |
| Blood glucose test | ||
| Not available | 1 | 1 |
| Available | 0.04 [0.002–0.156] | 0.044 [0.005–0.339] |
| Urine protein and ketone | ||
| Not available | 1 | 1 |
| Available | 0.023 [0.003–0.182] | 0.054 [0.006–0.472] |
| Metformin | ||
| Available | 1 | 1 |
| Not available | 0.006 [0.001–0.051] | 0.003 [0.000–0.066] |
| Glibenclamid | ||
| Not available | 1 | 1 |
| Available | 0.008 [0.001–0.67] | 0.008 [0.001–0.091] |
| Insulin | ||
| Not available | 1 | 1 |
| Available | 0.19 [0.005–0.77] | 0.018 [0.003–0.121] |
| Glucose 40% | ||
| Not available | 1 | 1 |
| Available | - | - |
| Gliclazide/Glipizide | ||
| Not available | 1 | 1 |
| Available | 0.193 [0.017–2.237] | 0.459 [0.011–19.545] |
Notes:
P value ≤ 0.05.
P value ≤ 0.01.